Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.42 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.42 |
| ▸ | NEK2 | P51955 | 2/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.42 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.42 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.42 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.42 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | PIR | O00625 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1873673 | 0.87 | BRAF (0.49) | BRAFABL1RIPK2RAF1KDR | |
| SCHEMBL12669237 | 0.83 | BRAF (0.51) | BRAFABL1RIPK2RAF1KDR | |
| SCHEMBL1882268 | 0.81 | BRAF (0.41) | BRAF | |
| SCHEMBL23458318 | 0.81 | CYP3A4 (0.48) | BRAF | |
| SCHEMBL29721342 | 0.81 | CYP3A4 (0.48) | BRAF | |
| SCHEMBL9986679 | 0.79 | BRAF (0.38) | BRAFABL1RIPK2RAF1KDR | |
| SCHEMBL1461831 | 0.76 | CYP3A4 (0.46) | BRAFABL1RIPK2RAF1KDR | |
| SCHEMBL1876513 | 0.76 | BRAF (0.39) | BRAFMAP2K4 | |
| SCHEMBL9931705 | 0.75 | CYP3A4 (0.45) | BRAFABL1RIPK2RAF1KDR | |
| SCHEMBL23478025 | 0.74 | SHMT1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230151-A1 | COMPOUNDS FOR CANCERS DRIVEN BY BRAF MUTATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2023070076-A1 | COMPOUNDS FOR CANCERS DRIVEN BY BRAF MUTATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230151-A1 | COMPOUNDS FOR CANCERS DRIVEN BY BRAF MUTATION | BRAF, ABCB1, NRAS | BRAF 1/4885ABL1 61/4885RIPK2 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.